Tempest Therapeutics Inc
Tempest Therapeutics specializes in cancer treatments through innovative approaches targeting the immune system.
Price history of Tempest Therapeutics Inc
Price history of Tempest Therapeutics Inc
Performance & Momentum
Strategic Analysis
Tempest Therapeutics Inc • 2026
Tempest Therapeutics is a clinical-stage oncology biotech focused on cancer therapies and other serious diseases. Its profile is that of a high-optionality research company, where value depends mainly on the success of clinical trials, regulatory progress, and the ability to finance its pipeline.
- Clear positioning in oncology, an attractive field where medical needs remain high
- Significant value-creation potential in the event of positive clinical results or a strategic deal
- Niche biopharmaceutical profile that could offer strong performance asymmetry
- Extreme dependence on clinical data and the development timeline
- Dilution risk and financial pressure typical of unprofitable biotech small caps
- Very poor stock-market track record, reflecting fragile investor confidence
Momentum is very weak and the underlying trend remains clearly bearish, reflecting a lack of market support despite the oncology theme. In practice, the stock remains highly speculative: it can rebound sharply on favorable clinical news, but it is still exposed to significant volatility and a risk of value destruction if execution falls short.
Similar stocks to Tempest Therapeutics Inc
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
